SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Liliʻuokalani

PatientLiliʻuokalani
Date of birth1947-09-02
IdentifiersMRN HR-ET024-SYN; SSN (made up) 000-24-3086
Document date2026-06-15
AuthorKealani Morrison-Takeda, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month review after the stroke. [S]

History of Present Illness

Liliʻuokalani returns three months after the stroke. She has had no new neurological symptoms. The nosebleed four weeks ago has not recurred since she began using a nasal gel and a humidifier. She takes apixaban twice daily and has missed no doses. She plays the piano and has resumed composing, though she tires at the end of a long day. Her home blood pressure averages 124/72. She had a video review with Dr. Abernethy-Sato last week, who agreed with apixaban and the current plan. She has had no falls. She sleeps well and does not snore, by her household's account. [S]

ElementDetail
FunctionComposing and playing daily; modified Rankin Scale 1
MoodPHQ-9 4
Home blood pressureAverage 124/72 mmHg
AnticoagulantNo missed doses; one minor nosebleed four weeks ago
SleepSTOP-Bang 2 (age and treated blood pressure)

Review of Systems

SystemResultFinding
NeurologicalNegativeNo weakness, numbness, speech, vision or balance problem
HematologicNegativeNo further nosebleeds; no black stools or blood in the urine
PsychiatricNegativeMood steady; sleeping well
ConstitutionalPositiveTired at the end of long days

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aspirin 81 mg delayed-release oral tablet, one tablet daily for 21 days, after a 325 mg loading dose in the emergency departmentOne tablet daily for 21 daysOral route2026-03-16 to 2026-04-06completedS
Clopidogrel 75 mg oral tablet, one tablet daily, after a 300 mg loading dose in the emergency departmentOne tablet dailyOral route2026-03-16 to 2026-04-20completedS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-16activeS
Losartan 25 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS
Apixaban 5 mg oral tablet, one tablet twice dailyOne tablet twice dailyOral route2026-04-20activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-15Body height160cmS
2026-06-15Body weight57.6kgS
2026-06-15Body mass index (BMI) [Ratio]22.5kg/m2S
2026-06-15Systolic blood pressure126mm[Hg]S
2026-06-15Diastolic blood pressure74mm[Hg]S
2026-06-15Heart rate70/minS
2026-06-15Respiratory rate16/minS
2026-06-15Body temperature36.6CelS
2026-06-15Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-06-15Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-06-15Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-06-15Creatinine [Mass/volume] in Serum or Plasma0.84mg/dL0.59-1.04 mg/dLNormalS
2026-06-15Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M71mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-06-15Glucose [Mass/volume] in Serum or Plasma95mg/dL70-99 mg/dLNormalS
2026-06-15Hemoglobin [Mass/volume] in Blood12.6g/dL11.6-15 g/dLNormalS
2026-06-15Modified rankin scale1{score}S
2026-06-15Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S

Physical Exam

Vital signs recorded on 2026-06-15; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 126/74, pulse 70 and regular; weight 57.6 kg
NeurologicalNormal speech, strength, fine finger movements and gait
NoseLeft anterior septum healed; no crusting
MusculoskeletalTimed Up and Go 11 seconds

Problems

ProblemClinical statusVerificationCodeProvenance
Transient weakness and clumsiness of the right hand with word-finding difficulty, lasting about 20 minutes and fully resolved, the afternoon before the visit; suspected transient ischemic attack, ABCD2 score 5 (high risk); NIH Stroke Scale 0resolvedprovisional G45.9S — Synthetic presenting problem; resolved into the stroke diagnosis when diffusion MRI showed a small infarct at the stroke clinic the next day. Not a claim about her real symptoms.
Minor ischemic stroke: a small acute infarct in the cortex of the left precentral gyrus (left middle cerebral artery territory) on diffusion MRI, embolic in pattern, with full recovery (NIH Stroke Scale 0); source found to be paroxysmal atrial fibrillation; synthetic modern episode linked to her documented death from a strokeactiveconfirmed I63.412S — Synthetic modern diagnosis made at the stroke clinic the day after the visit; the 1917 cause of death remains D.
Hypertension: told of borderline readings in past years and not treated; 156/88 mmHg at intakeactiveconfirmed I10S — Synthetic risk factor; no blood pressure from her lifetime is recorded in the cited sources.
Paroxysmal atrial fibrillation found on 30-day ambulatory monitoring after the stroke (six episodes, the longest 3 hours 10 minutes; burden about 3%); CHA2DS2-VASc 6, HAS-BLED 2activeconfirmed I48.0S — Synthetic finding on prolonged rhythm monitoring at five weeks.
Anterior nosebleed from the left side of the nasal septum four weeks after starting apixaban, stopped with pressure; hemoglobin unchanged; resolvedresolvedconfirmed R04.0S — Synthetic intercurrent problem at an unscheduled visit; a common minor bleed on an anticoagulant, not a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure in the clinic and at home (target below 130/80 mmHg) and weightEvery visitCompleted today126/74 mmHg; home average 124/72; 57.6 kg
LaboratoryPotassium and creatinine after starting an angiotensin receptor blockerAbout two weeks after starting, then every six monthsCompleted todayPotassium 4.4 mmol/L, creatinine 0.84 mg/dL (eGFR 71)
Medication safetyAntithrombotic therapy and adherenceEvery visitCompleted todayApixaban twice daily, no missed doses; one minor nosebleed, managed without stopping it
LaboratoryAnticoagulant safety: blood count, kidney function (creatinine clearance) and liver testsBefore starting, then about every creatinine clearance / 10 months at age 75 or older (about every five months for her)Completed todayHemoglobin 12.6 g/dL; creatinine 0.84 mg/dL
SurveyNeurological status (NIH Stroke Scale at the event; modified Rankin Scale at 90 days) and new symptomsModified Rankin Scale at 90 daysCompleted todayModified Rankin Scale 1; no new symptoms
SurveyDepression screen (PHQ-2, PHQ-9)At the first post-stroke visit, then at least yearlyCompleted todayPHQ-9 4; item 9 scored 0
SurveyCognitive screen (MoCA)After the event, again within the first year, then periodicallyUp to dateMoCA 26 after the stroke; repeat at the five-month review
LaboratoryLipid panel (LDL goal below 70 mg/dL)Four to twelve weeks after starting a statin, then every three to twelve monthsUp to dateLDL 64 mg/dL at five weeks; repeat at five months
ExaminationFalls riskEvery visitCompleted todayNo falls; Timed Up and Go 11 seconds
SurveyObstructive sleep apnea screen (STOP-Bang)After a strokeCompleted todaySTOP-Bang 2: low risk; no sleep study needed
ReferralRehabilitation (physical, occupational and speech therapy)At discharge and during recoveryNot indicatedNo residual deficit; modified Rankin Scale 1
Self-managementTobacco, alcohol and physical activityEvery visitCompleted todayNever smoker; alcohol rarely; walks daily
Self-managementBE FAST and calling 911Every visitCompleted todayReviewed
Self-managementCulturally safe care: her choices, ʻohana involvement and Native Hawaiian healing alongside clinic careEvery visitCompleted todayLomilomi continues by her choice; her ʻohana is involved as she wishes

Goal progress:

Guideline basis: 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association (2021); Primary Care of Adult Patients After Stroke: A Scientific Statement From the American Heart Association/American Stroke Association (2021); 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, atrial fibrillation and hypertension monographs (2026); Signs and Symptoms of Stroke (2026); Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026); Falls Prevention in Community-Dwelling Older Adults: Interventions (2024)

Follow-up: Annual wellness visit in four weeks. Five-month review in ten weeks with a lipid panel, blood count, kidney function and the MoCA. Call 911 for any BE FAST sign. Next scheduled visit 2026-07-13: subsequent annual wellness visit. [S]